New MenaQ7 vitamin K2 study published

Clinical intervention trial with haemodialysis patients shows positive, safe response

A new study of haemodialysis patients examined the risk factors and response to vitamin K2 supplementation, and confirmed this population’s specific need to correct vitamin K2 deficiency.

The study was published in BMC Nephrology and the vitamin K2 used in the study was MenaQ7 vitamin K2 as MK-7 from NattoPharma.

According to the researchers, the scientific data showed that the vitamin K2 intake in haemodialysis patients is estimated to be 40% lower than in the healthy individual group.

It has been accepted by the European medical society that haemodialysis patients are vitamin K deficient, and they can benefit from vitamin K2 supplementation.

However, this aspect had not yet been evaluated in Eastern Mediterranean populations.

“NattoPharma was excited to participate in this clinical intervention trial,” says Hogne Vik, Chief Medical Officer of NattoPharma.

“We have long recognised the important implications correcting a vitamin K2 deficiency can have on human health, particularly in patient populations who suffer intense vascular calcification as a result of their condition."

This study adds to the body of evidence confirming the cardiovascular support MenaQ7 vitamin K2 as MK-7 provides, and continues to solidify NattoPharma as the global leader in K2 research and development.”

The study, based in Lebanon, assessed if there is a correlation between vitamin K status and vascular calcification score in haemodialysis patients, and if K2 supplementation would improve extrahepatic vitamin K status in this Eastern Mediterranean populations.

Fifty haemodialysis patients were enrolled in this clinical study, and received daily 360µg of menaquinone-7 (MenaQ7) for 4 weeks.

Extrahepatic vitamin K status represented as the level of dpucMGP (dephosphorylated-uncarboxylated matrix Gla protein, or “inactive” MGP, a K-dependent protein) and vascular calcification scores (AC-24) were measured at the beginning and at the end of the vitamin K2 treatment.

The main conclusion was that hemodialysis patients have profound vitamin K deficiency as assessed by high dp-ucMGP plasma levels. High dpucMGP level was significantly correlated with high aortic calcification scores and thus can be used as a non-invasive marker for vascular calcifications.

According to the researchers: “The daily administration of 360µg of vitamin K2 (MK-7) decreased dpucMGP by 86% after 4 weeks and it was well tolerated. Further studies should be conducted to assess the change in vascular calcifications after an extended duration of therapy.”

Companies